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Abstract
In 2007, the first confirmed case of Cryptococcus gattii was reported in the state of North Carolina, USA. An otherwise
healthy HIV negative male patient presented with a large upper thigh cryptococcoma in February, which was surgically
removed and the patient was started on long-term high-dose fluconazole treatment. In May of 2007, the patient presented
to the Duke University hospital emergency room with seizures. Magnetic resonance imaging revealed two large CNS lesions
found to be cryptococcomas based on brain biopsy. Prior chest CT imaging had revealed small lung nodules indicating that
C. gattii spores or desiccated yeast were likely inhaled into the lungs and dissemination occurred to both the leg and CNS.
The patient’s travel history included a visit throughout the San Francisco, CA region in September through October of 2006,
consistent with acquisition during this time period. Cultures from both the leg and brain biopsies were subjected to
analysis. Based on phenotypic and molecular methods, both isolates were C. gattii, VGI molecular type, and distinct from the
Vancouver Island outbreak isolates. Based on multilocus sequence typing of coding and noncoding regions and virulence in
a heterologous host model, the leg and brain isolates are identical, but the two differed in mating fertility. Two clinical
isolates, one from a transplant recipient in San Francisco and the other from Australia, were identical to the North Carolina
clinical isolate at all markers tested. Closely related isolates that differ at only one or a few noncoding markers are present in
the Australian environment. Taken together, these findings support a model in which C. gattii VGI was transferred from
Australia to California, possibly though an association with its common host plant E. camaldulensis, and the patient was
exposed in San Francisco and returned to present with disease in North Carolina.
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Introduction
Significant medical advances have been achieved in the fields of
antimicrobial agents and vaccine development, yet both newly
emerging and re-emerging infectious diseases in humans, livestock,
and plants remain serious global health and economic burdens
[1,2]. Several factors influence the emergence and re-emergence of
infectious diseases, and two are globalization and an increasing
population of immunocompromised hosts [3,4]. These have
significantly impacted the emergence of systemic fungal infections
over the past two decades, largely due to widespread use of broad-
spectrum antibiotics, advances in healthcare, and the HIV
pandemic [5].
An essential component for tracking emergence and epidemi-
ology of bacterial, parasitic, and fungal infections is molecular
strain typing. In the genomic era, whole genome sequences have
allowed comprehensive typing though sequence-based methods,
including multilocus sequence and variable number of tandem
repeat (VNTR) typing approaches [6,7]. Each method has distinct
benefits for increasing typing resolution, and can be used
concomitantly to increase the overall power of molecular typing.
Multilocus sequence typing has been widely applied to the fungal
kingdom, and in particular for the Cryptococcus species complex
[8,9,10,11]. Fewer studies have applied VNTR analysis to fungal
pathogens, which was developed and is widely used in studies of
bacterial pathogens [7,12,13,14]. We present here the first
application of a combined MLST/VNTR approach to establish
relationships among a group of emerging Cryptococcus gattii clinical
and environmental isolates.
C. gattii is a basidiomycetous yeast closely related to other
members of the Cryptococcus pathogenic species complex, including
C. neoformans var. grubii and var. neoformans [15,16,17]. C. gattii has
often been associated with tropical and subtropical climates
including Australia and South America [15], and has emerged as a
fungal pathogen of humans and animals in temperate climates
including Vancouver Island, mainland British Columbia, Canada,
and the United States Pacific Northwest, including Washington
and Oregon [10,18,19,20,21,22,23]. The species C. gattii can be
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5851subdivided into serotypes B and C based on unique capsular
antigenic determinants [24,25]. In addition, the species can be
divided into four molecular types (VGI, VGII, VGIII, VGIV)
based on evidence from Amplified Fragment Length Polymor-
phisms (AFLP), Random Amplification of Polymorphic DNA
(RAPD), and Multilocus Sequence Typing (MLST) [10,11,26].
Genetic exchange between the four VG molecular types is rare,
indicating that these likely represent cryptic species [10,11].
Cryptococcosis is the disease caused by the pathogenic
Cryptococcus species complex and usually results in pulmonary
infection/pneumonia, central nervous system (CNS) dissemina-
tion, and in some cases cryptococcoma formation [17,27]. C.
neoformans and C. gattii share some common virulence attributes but
are also distinct. C. neoformans has a global distribution and
predominantly infects immunosuppressed hosts, while C. gattii is
more geographically restricted and commonly infects immuno-
competent individuals [28]. Incidence in immunocompetent
individuals is particularly high within the VGI and VGII
molecular types. Molecular type VGI commonly causes infections
in Australia, whereas the VGII molecular type is responsible for
the vast majority of cases related to the Vancouver Island
outbreak, and its expansion into the North American Pacific
NW [17,19,29]. The VGIII and VGIV molecular types have been
reported to infect immunocompromised patients, including HIV/
AIDS patients and organ transplant recipients [30,31,32].
In the United States and Canada, a major focus of C. gattii
research has been on molecular type VGII due to the high
percentage (,95%) of clinical cases caused by this molecular type
in otherwise healthy individuals, while only ,5% of cases result
from VGI infection [8,19,20]. While VGI is the most common
infectious molecular type globally and has been reported in
cryptococcosis cases from the Americas including Canada,
Mexico, and South America, the overall number of isolates from
the United States has been low [10,17]. In the United States there
have been two confirmed cases of C. gattii molecular type VGI,
both in California. One case occurred in a male Atlantic
bottlenose dolphin (Tursiops truncatus) in San Diego; the other was
in a liver transplant recipient in San Francisco [32,33]. The
isolates from these cases differed based on multilocus sequence
type (MLST) analysis, but both are closely related or identical to
isolates from Australia, indicating that an environmental source in
California may have originated from the large number of
Eucalyptus trees imported from Australia to California, particularly
due to the strong environmental association between the VGI
molecular type and Eucalyptus trees [10,34].
C. gattii has never been isolated from environmental sources in
the Eastern United States [35], and until the present study no cases
in the region have been reported in humans or animals. In this
study we present the first reported clinical case of C. gattii in the
Southeastern United States, which occurred in an immunocom-
petent individual residing in central North Carolina. We show that
this case, which resulted in large cryptococcomal granulomas in
the leg and brain, resulted from infection with a C. gattii VGI type
isolate that is distinct from both the common VGII and rarer VGI
isolates associated with the Vancouver Island/Pacific NW C. gattii
outbreak. The molecular genotype of the isolates from both leg
and brain biopsies show that the molecular profile based on
multilocus sequence (MLS) analysis of both coding (MLST) and
more variable noncoding (VNTR) markers is shared with only two
clinical isolates (one from Australia, and the other from an organ
transplant recipient in San Francisco, California) out of 85 VGI
strains typed [10,32]. While this is the first reported case in the
Eastern United States, the suspected ecological niche is in the
Western United States, and the patient’s travel history is consistent
with acquisition in the San Francisco metropolitan area. Travel to
endemic areas is known to increase risk for C. gattii exposure and
disease, and leads to acquisition in one region with presentation in
a distant location [36,37]. The Australian case, California
transplant patient, and North Carolina patient isolates are closely
related to, but not identical at all noncoding genomic markers
(VNTR) with Australian environmental isolates. Therefore, the
Australian environment is the most likely source of the original
isolates, and additional sampling may be necessary, as subtle
genetic changes may have occurred during expansion or infection.
Our results further support the well documented emergence of C.
gattii in temperate climates in the Western United States, and put
forth a model in which an emergence from Australia to California




Melanin production was assayed by growth and the production
of dark pigmentation on Staib niger seed agar medium, and urease
activity was detected by growth and alkaline pH change on
Christensen’s Agar. These tests established that isolates were either
C. neoformans or C. gattii. Isolates were then examined for resistance
to canavanine and utilization of glycine on L-canavanine, glycine,
2-bromothymol blue, (CGB) agar. Growth on CGB agar indicates
that isolates are canavanine resistant, and able to use glycine as a
sole carbon source, triggering a bromothymol blue color reaction
indicative of C. gattii, whereas C. neoformans is sensitive to
canavanine, and cannot use glycine as a sole carbon source,
resulting in no growth or coloration on this selective indicator
medium. Capsule identification was conducted though India ink
analysis and microscopy after growth on Dulbecco’s Modified
Eagle’s Medium (DMEM) for 72 hours at 37uC.
Molecular Typing
For multilocus sequence typing analysis (MLST), each isolate was
analyzed with a minimum of eight and in some cases eleven
unlinked loci [6,9,10]. For each isolate, genomic DNA was
extracted using the MasterPure
TM yeast DNA purification kit
(Epicentre Biotechnologies), PCR amplified, purified and se-
quenced. All primers used for the analysis were designed specifically
to amplify open reading frame (ORF) gene sequence regions
including those with non-coding DNA regions to maximize
discriminatory power (Table S1). All PCR products were
sequenced, and novel sequences were re-amplified and sequenced
for confirmation. Sequences from both forward and reverse strands
were assembled, and manually edited using Sequencher version 4.8
(Gene Codes Corporations). Based on BLAST analysis of the
GenBank database (NCBI), each allele was assigned a number [10].
GenBank accession numbers with corresponding allele numbers are
listed in the supplementary information (Table S2). For the
microsatellite analysis two software packages were used: Magellan,
a freely available software package developed by Dee Carter’s
laboratory at the University of Sydney (http://www.medfac.usyd.
edu.au/people/academics/profiles/dcarter.php) [38], and the
Tandem Repeat Finder (TRF) software package developed at
Boston University [39]. Sequences were assembled and edited using
Sequencher version 4.8 (Gene Codes Corporations) and aligned
using the Clustal X version 2.0 software package [40].
Fertility Analysis
Mating analysis was conducted on Murashige and Skoog (MS)
media, which contains myo-inositol that stimulates mating [41].
Travel-Acquired Fungal Disease
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10 to 14 days under dry conditions. Fertility was assessed by
microscopic examination for hyphae, fused clamp cells, basidia,
and basidiospore formation.
Virulence
Infection assays in the heterologous host Galleria mellonella
(greater wax moth) were conducted with a method similar to
previous studies [42]. All animals were purchased in bulk and a
single shipment used for each replicate virulence test (Van der
Horst Wholesale, St. Marys, Ohio). The infectious inoculum was
injected directly into the hemolymph via the penultimate or
ultimate pseudo-pods using a Hamilton syringe (Hamilton USA).
All experiments were conducted in duplicate with an infectious
dose of 1.0610
5 cells, and larvae were maintained in a 37uC
controlled environment. For each replicate virulence assay, 12–19
larvae were infected for each strain analyzed. Animals were
monitored at 24-hour intervals, and mortality was defined as the
cessation of movement upon probing and development of a
distinctive dark colorization.
Results
Clinical presentation of an unusual Cryptococcus infection
The patient is a 46-year-old male with an unremarkable past
medical history who noticed a hard mass on his medial right thigh.
The mass enlarged over the course of three weeks, but was not
painful, and the patient had no other symptoms. His primary care
physician evaluated the mass with a magnetic resonance imaging
(MRI) scan, which showed a 56464 centimeter mass in the inner
mid right thigh involving the adductor magnus muscle. The mass
had mild heterogeneous enhancement on T2 imaging (Figure 1A)
and some changes consistent with limited surrounding edema. The
radiographic appearance was most consistent with a malignancy,
and he underwent further radiographic investigation with chest,
abdominal, and pelvic computed tomography (CT) scans.
The chest CT scan revealed a spiculated 1.662 centimeter left
lower lobe lung mass with multiple, bilateral sub-centimeter
pulmonary nodules (Figure 1B). The patient underwent a
percutaneous biopsy of the thigh mass, and pathology demon-
strated soft tissue necrosis and thick walled, encapsulated
organisms that stained with Gomori Methenamine Silver (GMS)
and mucicarmine. The entire mass was surgically resected, and
cultures from the mass grew Cryptococcus. Further evaluation
demonstrated a serum cryptococcal antigen of 1:32, negative HIV
serologies, and a normal CD4 lymphocyte count.
No other symptoms were revealed by a detailed medical history,
but the patient was regularly exposed to birds in the workplace.
However, extensive local sampling of the workplace environment
and birdcages failed to reveal a local source of infection. The
patient was placed on 400 mg fluconazole a day, and did well until
three months later when he presented with a tonic-clonic seizure.
An MRI scan showed a large, enhancing mass in the left parietal
lobe and a similar appearing mass in the right cerebellar
hemisphere (Figure 1C–D). A biopsy of the parietal mass showed
numerous yeast cells, and cultures grew Cryptococcus.
After diagnosis, the patient was initially treated with ampho-
tericin B and flucytosine, but due to renal toxicity/nephropathy
was changed to oral high-dose fluconazole (800 mg daily). The
large size of the mass lesions despite antifungal therapy prompted
consideration that the infection might be due to Cryptococcus gattii,
and serotyping with commercial monoclonal antibodies (Iatron,
Tokyo, Japan) revealed the isolate to be serotype B, consistent with
C. gattii (T. Mitchell, A. Litvintseva, personal communication). The
patient had traveled to San Francisco five months prior to his
original presentation. He had never been to the Pacific Northwest,
Australia, South America or other C. gattii endemic regions and his
only foreign travel had been to Western Europe.
Sixteen months after the seizure he was completely asymptom-
atic on fluconazole 400 mg a day, and showed a significant
decrease in the cerebral cryptococcomas upon reevaluation with
magnetic resonance imaging (Figure 1E–F). The patient is
currently asymptomatic and continuing fluconazole treatment as
of February 2009 with a cryptococcal antigen titer testing positive
at 1:4. The patient will continue treatment, and be re-scanned in
the spring of 2009.
Phenotypic analysis reveals isolates are C. gattii
Initial identification and confirmation that the leg (EJB1-L) and
brain (EJB2-B) isolates were C. gattii was completed using several
phenotypic and molecular tests. Isolates were confirmed to be C.
gattii based on melanin production on Staib niger seed agar,
production of urease on Christensen’s agar, and resistance to
canavanine with glycine utilization on CGB agar (Figure S1).
Capsule production was assayed through India ink exclusion of
cells grown at 37uC for 72 hours in DMEM, resulting in high
levels of polysaccharide capsule indicative of pathogenic Cryptococ-
cus species (Figure S1). Isolates were determined to be mating type
a based on controlled mating assays with C. gattii VGIII isolates
NIH312a and B4546a. Although both isolates ultimately were
able to complete the sexual cycle with the a mating tester, and are
therefore a mating type, there was a severe and reproducible
defect in hyphae and basidiospore formation in mating assays with
isolate EJB2-B when compared with EJB1-L (Figure 2), with
similar results obtained using a mating type a crg1 tester strain
(data not shown). Differences in mating ability were also observed
in other similar or identical genotype isolates (B4496 and E296
(high fertility) vs. PAT12ISO1 and E310 (low fertility)) (Figure S2).
There were no other significant differences between the isolates
when comparing melanin production, growth at 37uC, growth on
CGB agar, and urease and capsule production (Figure S1).
Molecular analysis reveals isolates are VGI molecular type
Molecular studies were conducted to determine if this clinical
case was in any way related to the outbreak of C. gattii on
Vancouver Island that has now expanded to mainland British
Columbia, Washington, and Oregon. Genomic DNA of each
isolate was analyzed by MLST at a minimum of eight loci
(Figure 3). In addition to the mating analysis to determine the
mating type of each isolate, PCR and sequence analysis were used
to detect either of the two mating type-specific idiomorphs of the
SXI genes. Amplification and sequence analysis of the sex specific
SXI1a mating type gene, as well as the absence of the mating type
specific SXI2a gene, confirmed that both isolates had the a mating
type allele (MATa). MLST analysis also showed that all MLST
alleles were identical between both the leg biopsy (EJB1-L) and
brain biopsy (EJB2-B) isolates, and each typed as C. gattii molecular
type VGI (Figure 3).
Detailed analysis of the molecular profile, and comparison with
.280 global isolates including 85 VGI isolates indicated that while
the isolates were highly similar to the most common molecular
type (VGI), they were identical to only a unique subset in the
collection. To examine if these isolates were at all related to the
ongoing C gattii outbreak on Vancouver Island, Canada, and the
Pacific NW, we examined all VGI isolates from this region in
detail. A total of six VGI isolates have been reported from
Vancouver Island, and none of these matched the NC clinical case
based on MLST analysis [8]. Three Vancouver Island isolates
Travel-Acquired Fungal Disease
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(EJB1-L and EJB2-B) based on MLST analysis (Figure 3). Three
others (A2M R314, A2M R299, and A4M R64) share 7 MLST
alleles but differ at the GPD1 allele (Figure 3). Thus, none of the
Vancouver Island isolates are a direct match to the NC clinical
case isolates. Of the six reported Vancouver Island VGI isolates,
there are four different MLST genotypes (Figure 3A). Of these
genotypes two are clinical (human), one veterinary, and one
environmental. There are no identical matches between the
Vancouver Island VGI environmental and clinical isolates. Thus,
there are VGI genotypes in the environment but infections may
have been acquired elsewhere, although wild animal cases are
most often locally acquired. Currently, no VGI cases have been
reported in Washington or Oregon states, and the incidence of
VGI on Vancouver Island and surrounding areas in the Pacific
NW region remains low.
Figure2. Clinical isolatesexhibit mating differences. All matingcultures were incubated at room temperature in thedark, for 10 to 14 days in dry
conditions using the mating type a tester isolate B4546 as a partner on Mirashige and Skoog Media. The brain biopsy isolate exhibits reduced fertility as
evidenced by a marked delay and paucity in hyphal growth (A) whereas hyphal growth, basidia, and basidiospore formation indicative of sexual
reproduction is evident in matings with the leg biopsy isolate (B). All mating experiments were repeated and representative images are shown here.
doi:10.1371/journal.pone.0005851.g002
Figure 1. Imaging from diagnosis through recovery depicting the clinical course of C. gattii infection. A) MRI imaging of the upper thigh
cryptococcoma. B) CT imaging of a pulmonary nodule, likely to be a cryptococcal granuloma. C–D) MRI imaging of brain cryptococcomas after seizure
presentation at the emergency room. E–F) MRI imaging of brain cryptococcomas after long-term fluconazole treatment, with reduced mass.
doi:10.1371/journal.pone.0005851.g001
Travel-Acquired Fungal Disease
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MLST genetic profile to the NC isolate, nine were from the
environment in Renmark, Australia, and were isolated from
Eucalyptus tree hollows (Figure 3A) [43]. An additional Australian
environmental isolate (E554) shared all loci with the NC clinical
case with the exception of the mating type specific SXI idiomorph,
because this isolate is mating type a (Figure 3A). The two MLST
matched clinical isolates were both from human infections, one
from Australia and one from a blood sample from a liver
transplant recipient treated in San Francisco, California (Figure 3)
[32]. To further discriminate isolates, the MLST analysis was
extended to include three additional loci. This analysis included
the NC, CA, Vancouver Island, and Australian clinical cases as
well as representative Australian environmental isolates. However,
no polymorphisms were detected in the three clinical isolates
harboring the NC clinical case genotype using the additional
coding markers (Figure 3A). Based on neighbor joining phyloge-
netic analysis [40], in which seven MLST loci were concatenated
into 5.7 kb of contiguous sequence, the four discrete VG
molecular types were clearly distinct, and the VGI group was
separated into 20 sequence types (ST) (Figure 3B). All isolates with
an identical MLST type to the NC clinical case grouped into
sequence type 11 (ST-11), and were closely related to the more
common sequence type 12 (ST-12), which harbors the VGI
molecular type genomic reference strain WM276.
Multilocus sequence typing is a powerful approach to
discriminate isolates in a sequence-based method, but also relies
almost exclusively on the genomic coding sequences of conserved
genes. For the analysis of highly clonal populations such as the
VGI molecular type, variable non-coding and intergenic sequenc-
es, particularly tandem repeats, can enable more detailed
characterizations of populations by allowing closely related isolates
to be distinguished. Using microsatellite markers developed with
the Magellan Software suite, and Variable Number of Tandem
Repeat (VNTR) analysis with the Tandem Repeat Finder (TRF)
software, strains harboring identical MLST profiles to the isolates
from the patient in this study were analyzed (Figure 3). Analysis of
three independent VNTR markers showed that two of the markers
were identical in all ST-11 isolates (Figure S3), while marker
VNTR-15 was able to discriminate five of the Australian
environmental isolates from all clinical isolates (NC-clinical, CA-
clinical, Australia-Clinical) and the other five environmental
isolates from Australia with this molecular genotype, due to a 40
base pair deletion within the tandem repeat region (Figure 4). In
addition, analysis of microsatellite marker MS1 clearly distin-
guished the Renmark environmental isolates, which produced a
smaller PCR product (,380 bp) than the three clinical isolates
and VGI control isolate WM276 (,480 bp) (Figure 5A). A high
GA content and repetitive nature of this locus impeded sequence
analysis, as polymerase slippage resulted in low-quality sequence
Figure 3. Molecular typing and phylogeny of the North Carolina clinical isolates with global isolates. A) MLST reveals the leg and brain
isolates are identical with each other, and also identical with a distinct genotype predominantly from Australia, and in a single clinical case from
California, USA. B) Neighbor joining phylogenetic analysis based on sequences from seven MLST loci in panel A (SXI idiomorphs not included)
illustrates discrimination between four molecular types (VGI-VGIV), and displays the relationship of the clinical case presented in this study to global
genotypes observed, including all VGI genotypes thus far reported (including the Vancouver Island VGI genotypes), and the Vancouver Island/Pacific
NW outbreak genotypes VGIIa/major, VGIIb/minor, and VGIIc. Note that not all sequence types and strains in (B) are represented in (A).
doi:10.1371/journal.pone.0005851.g003
Figure 4. DNA sequence alignment of VNTR15 among 18 VGI isolates of C. gattii. The noncoding VNTR marker divides the isolates with an
identical MLST profile into two groups: one group contains two NC clinical isolates which are identical to one another, the other clinical isolates, and
five of the ten Renmark isolates, and the second group includes the remaining five Renmark isolates. A 40 bp deletion was observed in the following
isolates: E307, E554, E360, E296, and E278. In addition, a single nucleotide polymorphism (SNP) (66A R 66G) discriminated the VGI type strain isolate
WM276 from the other 17 VGI isolates (see red circle).
doi:10.1371/journal.pone.0005851.g004
Travel-Acquired Fungal Disease
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5851results. However, partial sequence affirmed that the products were
specific (data not shown). Isolate WM276 was distinguished from
the three clinical isolates based on a SNP in the GPD1 MLST
allele locus, a 4 bp deletion in the TOR1 MLST allele, a SNP in
VNTR3, and a SNP in VNTR15. In addition, the VNTR3
analysis further differentiated the NC, SF, and Australia ST-11
clinical isolates of interest from the Vancouver Island VGI ST-12
isolate A4MR64 (Figure S3). Overall, the analysis of variable
sequences further discriminated the three clinical isolates with this
unique MLST type from the environmental isolates from
Renmark, Australia with the same 8-loci MLST genotype
(Figure 5B). These data indicate that while MLST is informative,
it lacks sufficient resolution to discriminate isolates with highly
similar albeit distinguishable genotypes.
C. gattii VGI isolates are virulent in a heterologous host
To determine the relative virulence between environmental and
clinical isolates of the same MLST type as the North Carolina
clinical case, infection assays were conducted in the heterologous
host, Galleria mellonella (greater wax moth). The use of non-
mammalian hosts to study fungal virulence and host defense has
been increasingly applied and is now well established [42,44,45].
Although Lepidoptera are distantly related to mammals, results in
the wax moth larval model have been highly correlated with
results using murine infection models [42,46,47]. In the virulence
assay, isolates were injected at an infectious inoculum of 1610
5
cells, using 12 to 19 larvae per strain per replicate at 37uC. The
selected isolates analyzed were all significantly pathogenic
compared to PBS control infections (p,0.005) (Figure 6). There
was no marked difference between ST-11 environmental and
clinical isolates (p.0.2). In addition, the VGI type strain control
isolate (WM276) showed no difference in virulence to the tested
isolates (p.0.2). This uniformity in virulence between environ-
mental and clinical isolates is consistent with direct acquisition of
infections from an environmental source.
Figure 5. Molecular typing reveals that the Australian environmental isolates are distinct from clinical isolates. A) PCR product size
differences at locus VNTR-MS1 reveals that environmental isolates from Renmark harbor a deletion compared to the clinical isolates with the same
MLST genotype. Agarose gel electrophoresis of the VNTR-MS1 marker, illustrating an ,100 bp difference between the larger (EJB1-L, EJB2-B,
PAT12ISO1, B4496, WM276*), and smaller (E278, E549, E280, E306, E307, E569, E286, E296, E310, E554) PCR products. * Denotes that the sequenced
type strain WM276 is not identical to the other clinical isolates. The bold circles represent four clinical isolates (from three cases) that type as identical
through all genotypic tests conducted. B) A linear representation of the progressive genotypic analysis. As the number of markers increased, along
with the genetic variability, the number of isolates typing as identical to the North Carolina clinical case decreased. At the end of the genotypic
studies only two clinical isolates, previously identified from Australia and California, typed as identical with the present NC clinical case.
doi:10.1371/journal.pone.0005851.g005
Figure 6. North Carolina clinical isolates are pathogenic in a
heterologous host. Groups of 12 to 19 larvae of Galleria mellonella
were each infected with an infectious inoculum of 1.0610
5 cells of
isolates EJB1-L, EJB2-B, WM276, and E296. Survival was monitored and
plotted daily for 16 days. All isolates were significantly virulent
(p,0.005) in comparison with the mock control (sterile PBS) infection.
The experiment was replicated in duplicate with similar results in each
replicate, and representative results are shown here.
doi:10.1371/journal.pone.0005851.g006
Travel-Acquired Fungal Disease
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Our findings document the first C. gattii case reported in the
Eastern region of the United States. The most parsimonious
explanation is that an otherwise healthy patient was exposed in
California, resulting in disease presentation in North Carolina
approximately 4 to 6 months after travel to an endemic region.
This case highlights an overall increase in C. gattii infections in
apparently immunocompetent individuals in temperate climates.
The patient had no recent travel history to the Pacific Northwest
or to other C. gattii endemic regions, and based on molecular
typing the infectious isolate is not related to any of the VGII or
VGI isolates causing the ongoing Vancouver Island outbreak, and
its emergence into mainland British Columbia, Washington, and
Oregon [18,20,22,23,48]. These VGI clinical isolates are also
distinct from molecular types VGIII and VGIV (Figure 3B). C.
gattii molecular type VGI has never been reported from the
environment in California, but it seems likely to be present there
based on successful environmental isolation of C. gattii molecular
types VGII and VGIII in regions of California, including San
Francisco and San Diego, and the abundant presence of the host
Eucalyptus trees throughout the state [34,49].
Our current model suggests that this unique MLST VGI
genotype is located in the environment and clinical setting in
Australia, with probable environmental colonization in California,
resulting in human infections (Figure 7). These conclusions are
based on broad MLST analysis as well as analysis of four hyper-
variable tandem repeats located throughout the C. gattii genome.
The VNTR analysis showed that environmental isolates all differ at
one or two rapidly evolving genomic regions, but clinical and
environmental isolates that are identical at eight MLST loci are
quite closely related. All environmental isolates from Australia were
collected from a single location, and slight diversity in geographic
regions is expected [50]. In October 2007, seventy samples were
collected from Eucalyptus trees in San Francisco. No isolates of C.
neoformans or C. gattii were obtained. Therefore, expanded sampling
will be necessary to definitively elucidate the environmental source
of the clinical isolates. We therefore posit that the patient in this
report traveled to the San Francisco region, and was there exposed
to infectious spores or desiccated yeasts, resulting in colonization of
the lungs, and dissemination, disease progression, and presentation
with systemic infection of the leg and brain (Figure 7). Each of the
three clinical cases caused by this VGI genotype occurred
independently as there is no evidence of direct human-to-human
transmission with this pathogen, other then rare introgenic
transmissions. In addition, if in vivo changes during infection were
responsible for the clinical and environmental isolate molecular
differences we would have expected the clinical isolates to differ
from each other, and this is not the case (Figure 5B). Therefore, the
most parsimonious explanation is independent environmental-to-
human exposure, with the exact source yet to be identified in
Australia and in California. These studies demonstrate that
increased typing resolution can be achieved by combining coding
and noncoding genomic markers, which are abundantly available
for fungal pathogens with publicly available genome sequences.
Other clinical cases of C. gattii due to travel in endemic areas have
been recently reported. In 2007, a 51-year-old HIV negative male
from Denmark presented with C. gattii disease in Europe after
traveling to Vancouver Island, Canada [37]. Molecular analysis
established that the isolate was identical to the VGIIa/major
genotype responsible for the Vancouver Island outbreak [37].
Additionally, a study from the British Columbia Centre for Disease
Control indicated that intra-island travel or tourism on Vancouver
Island to highly endemic areas increases the likelihood of contracting
cryptococcosis [36]. These studies demonstrate the importance of
human travel to endemic areas as it relates to the acquisition and
presentation of cryptococcal disease. Many clinical laboratories in
non-endemic regions do not differentiate C. neoformans infections from
C. gattii infections; therefore, the incidence of travel associated C. gattii
infections may be more common than currently appreciated.
While many of the studies related to C. gattii infections in the
United States and Canada have focused on the Vancouver Island
outbreak, it has been known for several decades that C. gattii is also
endemic to the environment in regions of California, causing
Figure 7. Proposed model for the emergence of C. gattii in the United States. The original source is postulated to be Australia, where
identical clinical and closely related environmental isolates have been reported. Given that human-human transmission other than introgenic is
unknown, the most parsimonious model for geographically dispersed clinical isolates is that isolates identical to the clinical cases are present in the
environments in Australia and California, USA. In this model, the patient from the Southeastern United States traveled to the endemic area of CA, was
exposed to the pathogen by inhalation, and ultimately returned to present with disseminated disease in North Carolina, USA.
doi:10.1371/journal.pone.0005851.g007
Travel-Acquired Fungal Disease
PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e5851infections in both animals and humans. In 1991, an isolate of C. gattii
VGIIa/major outbreak genotype was sampled from a Eucalyptus
camaldulensis tree at Fort Point Park, in San Francisco, indicating a
natural occurrence in the same host tree that C. gattii is most
commonly associated with in Australia [10,34]. Several studies have
also documented a likely endemic zone in Southern California. A
large cohort of HIV positive patients with cryptococcal infections
from Los Angeles hospitals revealed that the infections were
principally the result of C. gattii serotype C infections [31]. In
addition, C. gattii VGI has been isolated from a marine mammal case
(bottlenose dolphin) near San Diego, and C. gattii VGIII has been
isolated from the natural environment in the San Diego, California
area [33,51]. These studies provide strong evidence that multiple
molecular types (VGI, VGII, VGIII) have been reported in
California indicative of a likely reservoir, possibly in Eucalyptus and
other tree species.
Hypotheses regarding the spread of global fungal pathogens from
common associations with plants have been previously reported. It
was recently shown that a basidiomycete, the sugarcane fungal
pathogen Ustilago scitaminea, was dispersed from Asia to Americaand
Africaduetoitsassociationwithinfected plantmaterial[52].C.gattii
has been isolated from E. camaldulensis trees in San Francisco, a
common host tree species, and C. gattii was recently found to
complete its natural sexual cycle during co-culture with this plant
under laboratory conditions [34,41,53]. Population genetics studies
of individual trees of E. camaldulensis have also shown that both
same-sex and opposite-sex mating is likely occurring in this
environmental niche [54]. These reports demonstrate the likelihood
that this unique VGI genotype migrated due to plant association,
and also leaves open the possibility of sexual reproduction occurring
in natural populations of this genotype in the environment.
Sexual reproduction among closely related genotypes has the
potential to increase pathogenicity of fungi and parasites [55,56]. In
C. gattii it has been postulated that same-sex mating among closely
related isolates could have both contributed to the formation of the
hyper-virulent VGIIa/major genotype responsible for the Vancou-
ver Island outbreak and to the ongoing production of infectious
propagules [10,57,58]. Another well-studied system is the eukary-
otic parasite Toxoplasma gondii, where limited mating among clonal
lineages is hypothesized to have resulted in increased virulence, and
may also have enabled this pathogenic microbe to be orally
transmitted from animals to humans [59,60]. The reasons for
mating differences among the isolates from the leg and brain of the
North Carolina C. gattii case may be genetic, or epigenetic, as all
other analysis indicates that these isolates are from a single rather
than mixed infection. Although the exact roles of C. gattii sexual
reproduction as it relates to virulence remain to be elucidated, the
ability of virulent isolates to retain mating ability suggest this process
may play a significant role in virulence and possibly also in the
production of infectious propagules.
As C. gattii continues to emerge in the United States and
elsewhere it is clear that the standardization of clinical testing to
identify species (C. neoformans/C. gattii) and cryptic species (VGI/
VGII/VGIII/VGIV) is essential. As illustrated by this case, C. gattii
infections may be particularly complicated to treat due to their
predilection to form cryptococcomas, especially in the brain, which
are difficult to manage and risk to surgical resection is considerable.
Although clinical laboratory testing at Duke University confirmed
that the leg and brain biopsy isolates were both fluconazole
sensitive, because of disease progression and the occurrence of
cryptococcomas, in which drug access is limited, clinical manage-
ment was difficult. Although the overall incidence of C. gattii disease
in the United States remains low, an increasing number of cases in
California, Oregon, Washington, and now North Carolina among
immunocompetent and immunocompromised individuals raise the
possibility that these represent the onset of an emergence in the
temperate climate of the Western United States.
Supporting Information
Figure S1 Clinical and Australian environmental C. gattii VGI
isolates exhibit mating differences. All mating cultures were
incubated at room temperature in the dark for 14 days in dry
conditions using the mating type a tester isolate B4546 as a partner
on Mirashige and Skoog Media. The clinical isolate B4496 (top
left) and the environmental isolate E296 (top right) are fertile.
There is a marked delay and paucity, or no hyphal growth in
matings with the clinical isolate PAT12ISO1 (bottom left), and the
environmental isolate E310 (bottom right).
Found at: doi:10.1371/journal.pone.0005851.s001 (51.87 MB
TIF)
Figure S2 Phenotypic characterization of C. gattii isolates. In
each panels A and B control isolates are as follows: top left, C.
albicans control (CA, isolate SC5314) Isolate; bottom left, C.
neoformans control (CN, isolate H99); bottom right, C. gattii control
(CG, isolate R265). In panel A, the experimental isolate (upper
right) is EJB1-L. In panel B, the experimental isolate is EJB2-B.
Each isolate of C. gattii produced melanin on Staib niger seed agar
(brown pigmentation), produced urease on Christensen’s agar
(pink coloration), and was resistant to canavanine and utilized
glycine on CGB agar (growth and blue coloration). C) Isolates
EJB1-L (left panel), and EJB2-B (right panel) each show similar
capsule sizes when exposed to India ink following growth on
DMEM media for 48 hours at 37A ˆuC.
Found at: doi:10.1371/journal.pone.0005851.s002 (5.82 MB TIF)
Figure S3 Analysis of VNTR markers. DNA sequence alignment
of VNTR markers among 18 VGI isolates of C. gattii.T h eV N T R 3
marker discriminates two of the ST12 isolates (WM276 and
A4MR64) from the other 16 VGI isolates. VNTR7 shows 100%
sequence identity between all 18 isolates examined (red circle
indicates SNP).
Found at: doi:10.1371/journal.pone.0005851.s003 (38.91 MB
TIF)
Table S1
Found at: doi:10.1371/journal.pone.0005851.s004 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0005851.s005 (0.06 MB
DOC)
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